The invention relates to the technical field of medicines, and discloses applications of N-(2-ethoxyphenyl)-N-hydroxyoctanediamide in preparing medicines for resisting hepatic fibrosis. The research shows that N2E has the obvious targeted inhibiting effect for HDAC, and the inhibiting effect is stronger than that of the original drug SAHA by 5 times or more; the animal hepatic fibrosis model has agood anti-fibrosis function and a good liver function protection function. The experiment result shows that N2E has the relatively strong hepatic fibrosis resistance for the hepatic fibrosis animal model induced by carbon tetrachloride, and can invert the fibrosis process, and restore the liver function. The function of resisting hepatic fibrosis for the HDAC targeted inhibitor of N2E has great significance for treating hepatic fibrosis diseases and inverting the injuries to the liver functions due to the fibrosis.